PTJ
TGTX icon

Paul Tudor Jones’s TG Therapeutics TGTX Stock Holding History

Paul Tudor Jones’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$352K Buy
+6,400
New +$262K ﹤0.01% 3031
2025
Q4 		– Sell
-16,300
Closed -$589K – 4050
2025
Q3 		$589K Buy
16,300
+5,100
+46% +$168K ﹤0.01% 2597
2025
Q2 		$403K Buy
+11,200
New +$417K ﹤0.01% 2727

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Paul Tudor Jones's TGTX Position: Q2 2026 in Review

Paul Tudor Jones opened a new position in TG Therapeutics (TGTX) in Q2 2026: 93,920 shares worth $5.16M. The stake represents 0.01% of the portfolio and ranks #1259 among its holdings. This is a return to the name: Paul Tudor Jones previously reported a position in TGTX as recently as Q4 2025.

Paul Tudor Jones first reported a position in TGTX in Q2 2016 and has held it in 16 quarters since. 426 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Paul Tudor Jones held 93,920 shares of TG Therapeutics worth $5.16M as of Q2 2026.
  • TG Therapeutics was a new Paul Tudor Jones position in Q2 2026.
  • TG Therapeutics made up 0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #1259 holding.
  • Paul Tudor Jones first reported a position in TG Therapeutics in Q2 2016 and has held it in 16 quarters since.
  • 426 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.